AstraZeneca gets CDSCO panel nod to study anticancer drug Durvalumab Medical Dialogues Team3 Jun 2022 1:30 PM GMTNew Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
